LBT-3627

LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) that can change the behavior of immune cells so they protect dopamine-producing cells rather than attacking them.[1] The drug is being studied for its potential use for Parkinson's disease.[2]

Function

LBT-3627 specifically targets the VIP2 receptor, unlike VIP.[3] The drug also affects microglia.[1] In addition, LBT-3627 is more durable in the body compared to VIP.[4]

History and development

Scientists at the University of Nebraska Medical Center and Longevity Biotech, Inc. first demonstrated the use of the drug in mouse models.[2][4]

A phase I trial for humans was planned for 2017,[4] but as of 2018 it was still in the preclinical development stage.[5]

gollark: PotatOS Things may collect any information which PotatOS Things may collect. This includes information such as: Information you provide. If you provide information, this may be stored and used in order to provide PotatOS™ functionality. This includes information such as settings, which are stored locally so that they can be read and utilized, and your files, if you make files, which are stored on disk and potentially in RAM so that they can be read back and displayed. All user input or all executed code, if some debug settings such as Protocol Epsilon and Extended Monitoring are enabled Internally generated information which may be indirectly derived from user input, such as your device’s UPID1, some PotatOS Registry contents and system debug logs. ComputerCraft system configuration information and identification information, which is sent to SPUDNETv2/PIR and stored with incident reports to assist with debugging and/or handling the source of the reports. In certain jurisdictions, we may ask for a valid ID (from accepted countries such as Kazakhstan, the Democratic People’s Republic of Korea, Sealand, the Freeish State of Gollarkia, Desmethylway, the Harmonious Jade Dragon Empire, or the Untied States) in limited circumstances. This is only for purposes.
gollark: Project COMPARTMENTAL SLATS.
gollark: Besides, it's more of a thing run by heavpoot and me.
gollark: We are not a COUNTRY.
gollark: For users who are citizens of the European Union, we will now be requesting permission before initiating organ harvesting. This software uses an army of frogs that throw cookies in the general direction of your computer. By using it, you agree that these frogs may throw cookies.

References
  1. Paddock, Catharine (December 17, 2015). "New drug that protects dopamine cells raises treatment hope for Parkinson's". Medical News Today. Retrieved December 18, 2015.
  2. "Pioneering Neuroprotective Results Achieved in Parkinson's Disease Preclinical Studies". PR Newswire. December 16, 2015. Retrieved December 21, 2015.
  3. Azevedo, Margarida (December 21, 2015). "New Drug Candidate Shows Promise in Animal Model of Parkinson's". Parkinson's News Today. Retrieved December 21, 2015.
  4. Block, Jonathan (December 17, 2015). "Drug That Protects Dopamine Cells Eyed as Parkinson's Treatment". Phychiatry Advisor. Retrieved December 21, 2015.
  5. "Research programme: peptide-based therapeutics - Longevity Biotech". AdisInsight. January 8, 2018. Highest Development Phases: Preclinical : Neurological disorders; Type 2 diabetes mellitus


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.